A PHASE 1 STUDY OF SU011248 IN COMBINATION WITH FOLFIRI (IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN) IN PATIENTS WITH METASTATIC COLORECTAL CANCER

ABSTRACT: Primary objectives: To assess the Maximum Tolerated Dose (MTD) and overall safety and tolerability of SU011248 in combination with FOLFIRI Primary endpoints: Objective Response Rate (ORR)

DISEASE(S): Metastatic Colorectal Cancer.

PROVIDER: 2517000 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR